Background
==========

Myocardial infarction (MI) initiates healing and repair responses, which include scar formation, angiogenesis and remodeling. Preliminary data suggested that late (beyond 24 hours) opening of occluded culprit infarct artery might have beneficial impact upon these processes, with subsequent clinical advantages \[[@B1]\]. The Occluded Artery Trial (OAT) was a randomized trial testing the clinical effect of mechanical reperfusion versus optimal medical therapy alone (MED) for totally occluded arteries in stable patients 3--28 calendar days following MI. The main trial was powered to evaluate clinical outcomes, and failed to show any additional benefit of the interventional treatment over optimal medical therapy \[[@B2]\]. The lack of observed clinical benefit with percutaneous coronary intervention (PCI) was also independent of the presence and degree of viability in the infarct zone \[[@B3]\]. Changing plasma levels of relevant biomarkers may reflect the dynamics of these processes more sensitively, and their assessment may provide additional pathophysiological insight into the main study clinical findings.

The primary purpose of the OAT Biomarker substudy was to evaluate the impact of mechanical revascularization on paired levels of *N*-*terminal* prohormone of brain natriuretic peptide (NT-proBNP) obtained at baseline and at 1 year of follow up; and secondly to assess the impact of the randomized treatment on dynamics of biomarkers related to post-infarction left ventricular remodeling, fibrosis and angiogenesis, including matrix metalloproteinases (MMP) 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 (TIMP-2), Vascular Endothelial Growth Factor (VEGF), and galectin-3.

Methods
=======

Study setting & population
--------------------------

The patients were eligible for OAT-Biomarker ancillary study when they consented for the parent trial OAT (ClinicalTrials.gov Identifier: NCT00004562). Due to lack of funding the study was performed in only 10 sites in Poland, two in Canada and a solitary site in the United States. The substudy was approved by Institutional Review Board at each participating center (Terenowa Komisja Bioetyczna Instytutu Kardiologii; University Health Network Research Ethics Board; Research Ethics Board, St. Michael's Hospital; Ethics Committee, Truman Medical Center) and patients provided separate written informed consent for the OAT-Biomarker ancillary study. During follow-up repeated blood sampling 1 year after randomization was performed. For ninety percent (62/70) of the patients paired (baseline *plus* on-year) blood samples were available.

Laboratory methods and study outcomes
-------------------------------------

Baseline samples were obtained prior to OAT randomization and repeated after one year. Blood samples were collected in tubes without anticoagulant. The samples were then centrifuged, and serum was stored frozen in aliquots at -20°C to -80°C at the enrolling site until shipped to the biomarker core laboratory at the Institute of Cardiology, where they were maintained at -80°C. Serum NT-proBNP (sandwich immunoassay) for this batched analysis were determined using an Elecsys 2010 (Roche Diagnostics GmbH, Mannheim, Germany). The analytic range of NT-proBNP assay extends from 5 to 35000 ng/L. The total coefficient of variation (CV) was 2.1% at a level of 181 ng/L and 1.8% at a level of 572 ng/L. Concentrations of matrix metalloproteinases, tissue inhibitor of metalloproteinase-2 and VEGF were assayed using quantitative sandwich enzyme immunoassay technique. The following Quantikine (R&D Systems, Inc., Minneapolis, MN, USA) tests were used: human/mouse MMP-2, total (sensitivity =0.16 ng/mL, intra- and inter-assay precision; CV = 5.7 and 8.2%), human MMP-9, total, (sensitivity = 0.156 ng/mL, intra- and inter-assay precision; CV = 2.9 and 7.9%), human TIMP-2 (sensitivity = 0.011 ng/mL, intra- and inter-assay precision; CV = 4.4 and 7.3%), human VEGF (sensitivity =9.0 pg/mL, intra- and inter-assay precision; CV = 4.5 and 7.0%). Concentration of galectin was estimated using human galectin-3 ELISA kit (Bender MedSystems GmbH, Vienna, Austria) (sensitivity = 0.12 ng/mL, intra- and inter-assay precision; CV = 6.4 and 11.4%).

The primary endpoint for this biomarker analysis was NT-proBNP percent change from baseline to 1 year. The dynamics of the other biomarkers comprised the secondary outcomes of the study. The primary clinical endpoint of OAT was a composite of death from any cause, reinfarction, or NYHA class IV heart failure with hospitalization or admission in a short-stay unit with follow up extending out to 7 years. The study clinical endpoints were adjudicated by an independent committee. The definition of reinfarction has been provided previously \[[@B2]\].

Statistical analysis
--------------------

Data management and statistical analyses were performed by the OAT data coordinating center. Baseline biomarkers were assessed as medians (interquartile range), clinical characteristics were assessed as frequencies/proportions or mean ± standard deviation (SD) and compared to the remaining main OAT patients, as well as by treatment groups (PCI vs. MED). The nonparametric median Wilcoxon test, t-test or chi square tests were used for comparisons as appropriate. The biomarker's levels were presented as medians (inter-quartile range), and compared by means of Wilcoxon Signed Rank test. Two-sided two-group t-tests at alpha = 0.05 were done for comparisons of biomarkers changes from baseline to 1-year.

To examine the impact of the study treatment on biomarker dynamics, change in biomarkers' levels between baseline and 1 year were compared by treatment assignment (PCI versus MED). The independent correlates of NT-proBNP and other biomarkers dynamics (change from baseline to one year levels) were assessed by means of regression analyses. The univariate models were run first to identify any predictor significant at 0.10 level. Then a backward selection was run on the multivariate model to determine the final predictors that were still significant at 0.05 level. The treatment group was forced into the multivariable models. For the biomarkers dynamics (baseline *versus* follow-up), biomarkers dynamics between PCI *versus* MED subgroups, and for regression models with NT-proBNP dynamics as the dependent variable, significance level was set at p \< 0.05. For other analyses significance level was set at p \< 0.01. All analyses are performed on an intention-to-treat basis.

With a targeted sample size of 200 patients and a predicted standard deviation of 50% for change in biomarker levels from baseline to 1 year, there would be 80% power to detect a 22% difference in NT-proBNP change between the treatment groups in the presence of a 15% drop-out rate. With the observed SD of 76% and sample size of 62 (paired samples), there was 80% power to detect a difference of 56% for the primary outcome of change in NT-proBNP levels from baseline to 1 year.

Results
=======

Baseline characteristics
------------------------

Patient characteristics at study baseline and comparison to the main OAT cohort are illustrated in Table [1](#T1){ref-type="table"}. The mean age of enrolled patients was 60.8 ± 8.8 years, all patients were white (p \< 0.001 when compared to the main OAT), and 17 (25%) were women. Patients enrolled in the biomarker substudy had a longer time from MI to randomization, less thrombolytic therapy for the index event, lower prevalence of multivessel disease, and higher use of lipid lowering medications and spironolactone (Table [1](#T1){ref-type="table"}). Overall, thirty seven biomarker study subjects were randomized to PCI while 33 were in the control arm. Patients randomized to medical therapy alone had less diabetes and received less thienopyridines, when compared to the PCI group (Table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics

                                                  ***OAT-Biomarker (N = 70)***   ***Remaining OAT (N = 2131)***                          
  ---------------------------------------------- ------------------------------ -------------------------------- ------ ---------------- ---------
  Age (years)                                                  70                         (60.8 ± 8.8)            2131    (58.5 ± 11)      0.097
  Women                                                        17                             24.3                467         21.9         0.637
  Race White                                                   70                             100                 1693        79.4        \<.001
  **Clinical history**                                                                                                                        
    Angina                                                     15                             21.4                480         22.5         0.829
    Myocardial Infarction                                      3                              4.3                 244         11.5         0.080
    Percutaneous intervention                                  4                              5.7                 101         4.7          0.574
    Congestive heart failure                                   1                              1.4                  51         2.4          1.000
    Hypertension                                               36                             51.4                1035        48.6         0.638
    Diabetes                                                   10                             14.3                444         20.8         0.183
    Insulin use                                                6                              8.6                 118         5.5          0.279
    Hypercholesterolemia                                       31                             44.3                1111        52.2         0.195
    Stroke                                                     4                              5.7                  59         2.8          0.138
    Cerebrovascular disease                                    5                              7.1                  77         3.6          0.125
    Peripheral vascular disease                                1                              1.4                  82         3.9          0.519
    Current Smoker                                             25                             35.7                834         39.1         0.564
    Family history CAD                                         29                             41.4                854         40.1         0.820
  Days from MI to randomization - median {IQR}                 70                          21{16--26}             2131      8{5--16}      \<.001
  **Index myocardial infarction**                                                                                                             
    Received thrombolytics                                     1                              1.4                 423         19.9        \<.001
    STE / Q wave / R loss                                      58                             82.9                1849        86.8         0.344
    Killip Class II-IV                                         11                             15.7                406         19.1         0.473
    Ejection Fraction                                          70                         (46.3 ± 9.7)            2115   (47.8 ± 11.1)     0.275
    Rales                                                      1                              1.4                 136         6.4          0.125
  **Clinical measures**                                                                                                                       
    Estimated GFR \<60 ml/min/1.73 m^2^                        8                              11.4                305         14.6         0.453
    Glucose \> =126 mg/dl                                      8                              11.6                556         28.8         0.002
    BMI (kg/m^2^)                                              69                         (26.7 ± 3.6)            2118    (28.6 ± 5.1)     0.003
    Heart rate (bpm)                                           70                         (69.3 ± 9.8)            2128    (71.9 ± 12)      0.076
    Systolic blood pressure (mmHg)                             70                        (120.4 ± 11.9)           2129   (120.8 ± 18.1)    0.831
  **Angiography**                                                                                                                             
    Infarct-related artery (IRA) --LAD                         19                             27.1                774         36.3        . 0.267
    Infarct-related artery (IRA) --Lcx                         11                             15.7                324         15.2       
    Infarct-related artery (IRA) --RCA                         40                             57.1                1033        48.5       
    Multivessel Disease                                        21                             30.4                358         16.9         0.004
    Collaterals                                                64                             92.8                1858        88.3         0.256
  **Medications**                                                                                                                             
    Aspirin                                                    68                             97.1                2037        95.6         0.767
    Thienopyridine                                             42                              60                 1287        60.4         0.947
    Warfarin                                                   3                              4.3                 212         9.9          0.150
    Beta blocker                                               65                             92.9                1867        87.6         0.187
    Calcium blocker                                            2                              2.9                 127          6           0.434
    Lipid lowering agent                                       68                             97.1                1720        80.7        \<.001
    Spironolactone                                             9                              12.9                115         5.4          0.008
    ACE-Inhibitor or ARB                                       62                             88.6                1709        80.2         0.082

ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP, blood pressure, CAD-coronary artery disease, GFR-glomerular filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left circumflex coronary artery, RCA-right coronary artery, STE-ST elevation.

###### 

Baseline biomarker and patient characteristics by treatment assignment

                                                  ***PCI (N = 37)***   ***MED (N = 33)***                            
  ---------------------------------------------- -------------------- -------------------- ---- -------------------- --------
  **Biomarkers**                                                                                                         
    Baseline NT-proBNP(ng/L){IQR}                         37           846.1{402.4,1488}    33    1100{474.6,1726}    0.306
    Baseline VEGF(pg/mL){IQR}                             31            42.5{23.6,207.2}    27    37.5{17.4,70.2}     0.293
    Baseline MMP-2(ng/mL){IQR}                            33           185.7{172.3,216.9}   28   185.3{172.1,239.7}   0.879
    Baseline MMP-9(ng/mL){IQR}                            33               90{56,185}       28   102.3{44.2,163.2}    0.506
    Baseline TIMP-2(ng/mL){IQR}                           33            64.5{57.6,74.1}     28     64.3{59.2,70}      0.789
    Baseline GALECTIN(ng/L){IQR}                          33             12.8{9.8,15.5}     28      13{9.2,14.9}      0.806
  Age (years)                                             37              (62.5 ± 9.1)      33      (58.8 ± 8.1)      0.086
  Female                                                  11                  29.7          6           18.2          0.261
  Race White                                              37                  100           33          100             .
  **Clinical History**                                                                                                   
    Angina                                                8                   21.6          7           21.2          0.967
    Myocardial infarction                                 1                   2.7           2           6.1           0.599
    Percutaneous coronary intervention                    3                   8.1           1            3            0.616
    Congestive heart failure                              0                    0            1            3            0.471
    Hypertension                                          21                  56.8          15          45.5          0.345
    Diabetes                                              2                   5.4           8           24.2          0.038
    Insulin use                                           1                   2.7           5           15.2          0.093
    Hypercholesterolemia                                  15                  40.5          16          48.5          0.504
    Stroke                                                2                   5.4           2           6.1           1.000
    Cerebrovascular disease                               2                   5.4           3           9.1           0.661
    Peripheral vascular disease                           1                   2.7           0            0            1.000
    Current Smoker                                        13                  35.1          12          36.4          0.915
    Family history CAD                                    12                  32.4          17          51.5          0.106
  Days from MI to randomization - median {IQR}            37               22{17--26}       33       20{14--25}       0.135
  **Index myocardial infarction**                                                                                        
    Received thrombolytics                                1                   2.7           0            0            1.000
    STE / Q wave / R loss                                 30                  81.1          28          84.8          0.676
    Killip Class II-IV                                    7                   18.9          4           12.1          0.522
    Ejection fraction                                     37               (46.8 ± 9)       33     (45.7 ± 10.5)      0.652
    Rales                                                 0                    0            1           3.1           0.464
  **Clinical measures**                                                                                                  
    Estimated GFR \<60 ml/min/1.73 m^2^                   5                   13.5          3           9.1           0.714
    Glucose \> =126 mg/dl                                 2                   5.6           6           18.2          0.140
    BMI (kg/m^2^)                                         37              (26.4 ± 2.8)      32      (27.2 ± 4.3)      0.365
    Heart rate (bpm)                                      37              (68.9 ± 9.4)      33     (69.7 ± 10.3)      0.733
    Systolic blood pressure (mmHg)                        37             (119.5 ± 11.4)     33     (121.4 ± 12.5)     0.507
  **Angiography**                                                                                                        
    Infarct-related artery (IRA) LAD                      13                  35.1          6           18.2          0.240
    Infarct-related artery (IRA) Lcx                      6                   16.2          5           15.2         
    Infarct-related artery (IRA) RCA                      18                  48.6          22          66.7         
    Angiography - multivessel disease                     9                   24.3          12          37.5          0.236
    Collaterals                                           36                  97.3          28          87.5          0.175
  **Medications**                                                                                                        
    Aspirin                                               36                  97.3          32           97           1.000
    Thienopyridine                                        34                  91.9          8           24.2          \<.001
    Warfarin                                              0                    0            3           9.1           0.100
    Beta blocker                                          32                  86.5          33          100           0.056
    Ca blocker                                            1                   2.7           1            3            1.000
    Lipid lowering agent                                  35                  94.6          33          100           0.494
    Spironolactone                                        6                   16.2          3           9.1           0.485
    ACE-Inhibitor or ARB                                  32                  86.5          30          90.9          0.714

\*median(interquartile range) for biomarkers, ACE-angiotensin converting enzyme, ARB-angiotensin receptor blocker, BMI-body mass index, BP = blood pressure, CAD-coronary artery disease, GFR-glomerular filtration rate, IQR-interquartile ranges, IRA-infarct related artery, LAD-left anterior descending artery, LCX-left circumflex coronary artery, MED -- medical therapy alone, PCI- percutaneous coronary intervention, RCA-right coronary artery, STE-ST elevation.

Biomarkers
----------

Baseline levels of NT-proBNP were 944.8 (455.3, 1533) ng/L and decreased by 69% to 266.8 (138.2, 584.9) ng/L during follow-up (p \< 0.0001). During this period MMP-2 \[185.7(172.3, 219.4) ng/mL versus 216.9 (176, 249.9) ng/mL, p = 0.034\] and TIMP-2 levels \[64.5 (58.6, 71) ng/mL versus 69.1 (62.6, 74.4) ng/mL, p = 0.027\] increased significantly from baseline to follow-up. In contrast, MMP-9 levels decreased from 101.6 (53.5, 170.2) ng/mL to 80.2 (43.7, 150.2) ng/mL (p = 0.038) while levels of VEGF \[39.9 (21.7, 83.7) pg/mL vs. 48.3 (19.6, 82.5) p = 0.291\], and Galectin \[12.8 (9.4, 15.2) ng/mL vs. 12.8 (10.1, 15.4) ng/mL, p = 0.561\] remained stable (Figure [1](#F1){ref-type="fig"}).

![**Baseline to one-year, median percent change of the biomarker levels; NT-proBNP-*N*-*terminal*prohormone of brain natriuretic peptide; MMP-matrix metalloproteinase; TIMP - tissue inhibitor of matrix metalloproteinase; VEGF-Vascular Endothelial Growth Factor.**](1471-2261-13-91-1){#F1}

Impact of PCI on biomarker levels
---------------------------------

The percent change from baseline to one year levels of NT-proBNP was significant within both PCI and MED subgroups. There was a trend toward increased MMP-2 in medically treated patients only, and MMP-9 tended to decrease in PCI but not in medically treated patients (Figure [2](#F2){ref-type="fig"}). Follow-up levels of the examined biomarkers and their changes over time did not differ significantly for the PCI versus MED subgroups (Figure [2](#F2){ref-type="fig"}).

![**Baseline to one-year changes of the examined biomarkers' levels by the study treatment (recanalization of infarct related artery (PCI) versus medical therapy alone (MED)). (A)** - NT-proBNP- *N*-*terminal* prohormone of brain natriuretic peptide; **(B)** - VEGF-Vascular Endothelial Growth Factor; **(C)** - MMP-2-matrix metalloproteinase-2; **(D)** - MMP-9-matrix metalloproteinase-9; **(E)** - TIMP-2 - tissue inhibitor of matrix metalloproteinase-2; **(F)** - Galectin.](1471-2261-13-91-2){#F2}

Predictors of the biomarkers' dynamics
--------------------------------------

The univariate and multivariable predictors of biomarker changes over time are provided in Table [3](#T3){ref-type="table"}. Percent change of NT pro-BNP was predicted independently by its baseline level and family history of coronary disease. For the other biomarkers, their dynamics were independently predicted by their respective baseline values. Additionally, changes in VEGF were correlated to previous thrombolytic therapy; while changes in TIMP-2 were related to history of renal insufficiency, baseline heart rate and BMI. Galectin changes were related to BMI (Table [3](#T3){ref-type="table"}).

###### 

Uni- and multivariable predictors of the biomarkers dynamics (change from baseline to one-year)

                  **Univariable model**                 **Multivariable model**                               
  --------------- ------------------------------------ ------------------------- ------------- -------------- -------------
  **NT-proBNP**   Baseline NT-proBNP                          **-0.699**          **\<.001**     **-0.695**    **\<.001**
                  PCI versus med                              **-6.939**           **0.979**    **-253.604**    **0.162**
                  Famliy history of CAD                      **-511.007**          **0.052**    **-448.534**    **0.015**
                  New Q waves                                **-531.444**          **0.067**       **-**          **-**
  **VEGF**        Baseline VEGF                               **-0.750**          **\<.001**     **-0.727**    **\<.001**
                  PCI versus med                              **-42.952**          **0.109**     **-5.514**     **0.694**
                  History of cerebrovascular disease         **-108.966**          **0.065**       **-**          **-**
                  Current smoker                              **-53.395**          **0.049**       **-**          **-**
                  Thrombolytic therapy                        **220.645**          **0.026**    **171.550**    **\<0.001**
  **MMP-2**       Baseline MMP-2                              **-0.982**          **\<.001**     **-0.979**    **\<.001**
                  PCI versus med.                             **-51.316**          **0.351**    **-11.677**     **0.384**
                  systolic blood pressure (10 mmHg)           **40.239**           **0.079**       **-**          **-**
                  diastolic blood pressure (10 mmHg)          **62.034**           **0.053**       **-**          **-**
  **MMP-9**       Baseline MMP-9                              **-0.751**          **\<.001**     **-0.742**    **\<.001**
                  PCI versus med.                             **-24.601**          **0.436**     **0.526**      **0.981**
                  MI history                                  **122.755**          **0.081**    **104.471**     **0.032**
                  History of cerebrovascular disease         **-185.871**          **0.006**       **-**          **-**
                  Current smoker                              **-58.054**          **0.068**       **-**          **-**
  **TIMP-2**      Baseline TIMP-2                             **-0.919**          **\<.001**     **-0.885**    **\<.001**
                  PCI versus med.                              **0.412**           **0.914**     **-2.558**     **0.255**
                  Male versus Female                           **8.349**           **0.049**       **-**          **-**
                  History of Renal Insufficiency              **17.714**           **0.085**     **22.685**     **0.003**
                  Family history of CAD                        **6.314**           **0.099**       **-**          **-**
                  Current smoker                              **-7.321**           **0.056**     **-5.025**     **0.029**
                  Heart rate (10 beats/minute)                 **3.213**           **0.099**     **3.566**      **0.002**
                  BMI (10 kg/m^2^)                            **-9.403**           **0.087**    **-11.541**    **\<0.001**
  **GALECTIN**    Baseline GALECTIN                            **-0.82**          **\<.001**     **-0.77**     **\<.001**
                  PCI versus med.                             **-0.734**           **0.674**     **0.037**      **0.975**
                  Angina history                              **-3.418**           **0.087**       **-**          **-**
                  PCI history                                  **6.348**           **0.059**       **-**          **-**
                  Thrombolytic therapy                        **-13.353**          **0.040**    **-10.305**     **0.023**
                  BMI (10 kg/m^2^)                             **8.281**          **\<0.001**    **7.326**     **\<.001**
                  Ejection fraction (10%)                     **-1.983**           **0.018**       **-**          **-**

NT-proBNP- *N*-*terminal*prohormone of brain natriuretic peptide, matrix metalloproteinase-MMP, tissue inhibitor of matrix metalloproteinases- TIMP, Vascular Endothelial Growth Factor -VEGF.

BMI-body mass index, CAD-coronary artery disease, MED-medical therapy, MMP-matrix metalloproteinase; NT-proBNP- *N*-*terminal*prohormone of brain natriuretic peptide; PCI-percutaneous coronary intervention; TIMP - tissue inhibitor of matrix metalloproteinase; VEGF-Vascular Endothelial Growth Factor.

Discussion
==========

This is a small, serial measurement of biomarkers substudy performed under the auspices of a large phase 3 rigorously performed randomized clinical trial. Despite its small size, the unique patient characteristics and the protocol assigned PCI in the background of a late totally occluded infarct related artery makes these observations notable. The differences in baseline characteristics from the parent trial likely reflect geographic characteristics arising from randomization in Poland which accounted for all of the paired samples considered for analysis. Prior analyses of the main trial demonstrated similar treatment effect across regions. Our study demonstrated that the plasma levels of biomarkers related to LV function and remodeling, including NT-proBNP, MMP-2, TIMP-2 and MMP-9, significantly evolved from baseline to one year following index MI. However, the change in biomarkers levels were not significantly modified by mechanical opening of the occluded infarct related artery (IRA) performed 3 to 28 days post MI.

NT-proBNP is an established biomarker used for diagnosis, prognosis and in selected cases management of patients with heart failure or acute coronary syndromes. It is synthesized in the ventricular myocardium in response to increased wall tension, myocardial stretch or ischemia \[[@B4]-[@B6]\]. The kinetics of NT-proBNP in the early post infarction period have been previously reported. An early rise is seen beginning immediately after the index infarct that has a second peak at about 24 hours. Subsequently NT-proBNP levels plateau at approximately 35 days. Plasma levels of NTpro-BNP chave been shown to correlate with cardiac function following myocardial infarction \[[@B7]\], as well as with mortality in heart failure or acute coronary syndromes. Serial changes of NT-proBNP parallel improving or worsening LV function \[[@B8],[@B9]\]. In a substudy of FRISC-II trial, higher baseline levels of NT-proBNP were shown to identify the subgroup of NSTE-ACS patients benefitting from interventional treatment \[[@B10]\]. The decline of NT-proBNP observed in OAT-Biomarker likely reflects gradual improvement of cardiac function (ejection fraction) directly observed in OAT-NUC and TOSCA 2 ancillary studies \[[@B3],[@B11]\]. We observed a lack of impact of the IRA recanalization on biomarker changes over one year. These findings are consistent with the lack of clinical benefit observed with PCI in the parent trial. Importantly, majority (89%) of the study patients received ACE inhibitors or angiotensin receptor-1 blockers, therefore the hypothetical impact of the study PCI was tested on top of optimal medical therapy, which itself had been shown to lower natriuretic peptide levels in patients with LV dysfunction \[[@B12]\].

Matrix metalloproteinases (MMP) and their tissue inhibitors (TIMPs) are enzymes involved in the extracellular matrix turnover and cardiac remodeling following infarction. Their release and roles following MI are time dependent \[[@B13],[@B14]\]. Prior studies reported a cause-effect relation between MMP-2,-9 and adverse LV myocardial remodeling after MI \[[@B15],[@B16]\]. MMP-2 and -9 levels were shown to correlate with echo measures of LV remodeling and non scarred myocardial mass on CMR \[[@B17]-[@B19]\]. Existing evidence supports clinical testing of MMP inhibitors for prevention of postinfarction remodeling in humans \[[@B13],[@B20]\].

In our cohort the values of MMP-2 significantly increased, while MMP-9 decreased from baseline. Similar shifts in these biomarker levels during long-term follow-up were previously observed in patients after MI \[[@B17],[@B18],[@B21],[@B22]\]. In our study, PCI tended to decrease MMP-9 levels more significantly than medical therapy alone (respectively 38% vs. 5%). Regarding MMP-2, PCI had no visible effect on its dynamics.

TIMP-2 may either inhibit or stimulate activation of MMP-2 \[[@B23],[@B24]\]. Its deficiency has been shown to accelerate post infarction LV remodeling in an animal model \[[@B25]\]. Plasma levels of TIMP-2 have been shown to increase in late stages of MI, as we observed in our cohort \[[@B17]\]. In the current study, TIMP-2 rise was positively correlated with history of renal insufficiency and heart rate and negatively with body mass index. However, PCI of IRA did not significantly impact alterations in these marker dynamics.

VEGF is implicated in neovascularization of ischemic tissue and wound healing, and its levels were previously shown to be correlated with peak creatine kinase levels in patients with MI. VEGF elevation has also been shown to be associated with clinical myocardial ischemia and adverse outcomes following ACS \[[@B26],[@B27]\]. The only independent correlate of the VEGF dynamics in our study was thrombolytic therapy for the index event. We did not find any association between the study treatment and baseline to one-year change of VEGF levels.

Experimental observations suggest that galectin-3 may be regarded not only as a biomarker but also as an active mediator of fibrosis causing progression of heart failure \[[@B28],[@B29]\]. In the clinical setting galectin-3 levels have been shown to correlate with clinical outcomes in patients with heart failure, providing incremental prognostic value to NT-proBNP \[[@B30]\]. In our study no significant difference was found between median baseline and follow up values of galectin, nor between PCI and medically treated patients. However, multivariable analysis identified thrombolytic therapy and BMI as independent correlates of the biomarker dynamics over one-year.

Limitations
-----------

The study cohort represents a small series of patients enrolled in the main OAT study. The power to detect small differences in the biomarker dynamics between the PCI and MED groups was limited due to the insufficient recruitment relative to initial projections. It is also conceivable that the differences between the study groups would differ had the patients been followed for a longer period of time. Only paired samples at baseline and 1 year of follow up were available. As a result the time course of changes during this window could not be elicited.

Conclusions
===========

The Biomarker ancillary study to OAT suggests that there are significant dynamic changes (from baseline to one year) in biomarkers related to LV remodeling, stress, and fibrosis following MI, however, their dynamics are not significantly modified by opening of occluded IRA 3 days-28 days post MI. Consistent with the findings of the parent trial and the nuclear substudy, our findings appear to also suggest that late IRA recanalization does not significantly impact mechanisms underlying LV healing/remodeling processes following MI in patients on optimal medical therapy.
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